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ABSTRACT
Some patients with interstitial lung diseases
(ILDs) other than idiopathic pulmonary fibrosis
exhibit a progressive clinical phenotype. These
chronic progressive fibrosing ILDs have a vari-
ety of underlying diseases, and their prevalence
is currently unknown. Here we carry out the
first systematic review of literature on the
prevalence of fibrosing ILDs and progressive
fibrosing ILDs using data from physician sur-
veys to estimate frequency of progression
among different ILDs. We searched MEDLINE
and Embase for studies assessing prevalence of
ILD, individual ILDs associated with fibrosis and
progressive fibrosing ILDs. These were com-
bined with data from previously published
physician surveys to obtain prevalence esti-
mates of each chronic fibrosing ILD with a
progressive phenotype and of progressive
fibrosing ILDs overall. We identified 16 publi-
cations, including five reporting overall ILD
prevalence, estimated at 6.3–76.0 per 100,000
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people in Europe (four studies) and 74.3 per
100,000 in the USA (one study). In total,
13–40% of ILDs were estimated to develop a
progressive fibrosing phenotype, with overall
prevalence estimates for progressive fibrosing
ILDs of 2.2–20.0 per 100,000 in Europe and 28.0
per 100,000 in the USA. Prevalence estimates for
individual progressive fibrosing ILDs varied up
to 16.7 per 100,000 people. These conditions
represent a sizeable fraction of chronic respira-
tory disorders and have a high unmet need.
Keywords: Epidemiology; Fibrosis; Interstitial
lung disease; Prevalence; Progressive
Key Summary Points
A proportion of interstitial lung diseases
(ILDs) (other than idiopathic pulmonary
fibrosis) that are associated with a variety
of underlying conditions may have a
common chronic progressive phenotype,
but the prevalence of such progressive
fibrosing ILDs is currently unknown
We have reviewed the literature to
estimate the prevalence of different
fibrosing ILDs, but there are few data on
prevalence of a progressive fibrosing
phenotype
The frequency of progression among
different fibrosing ILDs has been
estimated in a physician survey, and we
have used these estimates in combination
with published prevalence estimates for
fibrosing ILDs to estimate the overall
prevalence of progressive fibrosing ILD
The overall prevalence estimates for
progressive fibrosing ILDs were 2.2–20.0
per 100,000 in Europe and 28.0 per
100,000 in the USA, with 13–40% of ILDs
estimated to develop a progressive
fibrosing phenotype
DIGITAL FEATURES
This article is published with digital features,
including a summary slide, to facilitate under-
standing of the article. To view digital features
for this article go to https://doi.org/10.6084/
m9.figshare.13247072.
INTRODUCTION
The term ‘‘interstitial lung disease’’ (ILD)
encompasses a heterogeneous group of pul-
monary disorders, characterised by diffuse
parenchymal lung infiltration [1–3]. Pulmonary
fibrosis is common to many ILDs with differing
underlying diseases. Some ILDs can develop a
progressive fibrosing phenotype, characterised
by worsening fibrotic changes on high-resolu-
tion computed tomography (HRCT) of the
chest, decline in lung function over time,
worsening symptoms and quality of life, and
early mortality [4–6]. Patients who develop this
phenotype are collectively described as having
progressive fibrosing ILD [5–7]. Idiopathic pul-
monary fibrosis (IPF) is generally recognised as
the archetypal progressive fibrosing ILD [8].
However, a progressive fibrosing phenotype can
develop in other ILDs, including idiopathic
non-specific interstitial pneumonia (iNSIP),
hypersensitivity pneumonitis (HP) and ILDs
associated with autoimmune disorders, in par-
ticular rheumatoid arthritis-associated ILD (RA-
ILD) and systemic sclerosis-associated ILD (SSc-
ILD) [5, 7]. Not all patients with these ILDs will
develop a progressive fibrosing phenotype, but
those that do demonstrate a similar disease
course and prognosis to patients with IPF [6, 7].
Although there is a broad agreement among
experts that these conditions are rare, of debil-
itating nature and associated with high mor-
tality, there are few published data on overall
prevalence of progressive fibrosing ILDs [9–11].
Estimation of prevalence of progressive fibros-
ing ILD has methodological challenges due to
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the rarity of the disease, the lack of an estab-
lished definition, the broad spectrum of under-
lying diseases and difficulty in establishing
specific diagnoses; the prior lack of approved
treatment for most progressive fibrosing ILDs
further compounds this challenge. ILDs with a
chronic progressive phenotype have been the
subject of recent review articles [4, 12, 13], but
these have not attempted to estimate preva-
lence and rates of progression in a systematic
manner.
A phase III clinical trial has investigated the
efficacy and safety of nintedanib in patients
with differing clinical ILD diagnoses [7] who
presented with features of a diffuse fibrosing
lung disease of greater than 10% extent on chest
HRCT and had clinical signs of progression
(Table S1 in the electronic supplementary
material) [7]. Compared with placebo, ninteda-
nib significantly reduced the annual rate of
decline in forced vital capacity (FVC) in these
patients [14]. The potential availability of
treatment for progressive fibrosing ILD ampli-
fies the importance of better understanding the
epidemiology of these conditions, thereby
enabling a more precise quantification of the
unmet medical needs.
The objective of this systematic literature
review was to assess the overall prevalence of
ILDs, the overall prevalence of progressive
fibrosing ILDs and the prevalence of individual
ILDs that may develop a progressive fibrosing




Literature searches were conducted in August
2017 using MEDLINE and Embase electronic
bibliographical databases to identify publica-
tions reporting the prevalence of ILD, the
prevalence of individual ILDs and the preva-
lence of progressive fibrosing ILDs. Thesaurus
terms (MeSH and Emtree for MEDLINE and
Embase, respectively) and subject headings were
combined with free-text keywords; full search
strategies are outlined in Table S2.
To ensure that relevant publications were
not missed as a result of indexing delays, man-
ual searches of the American Journal of Respira-
tory and Critical Care Medicine, New England
Journal of Medicine and European Respiratory
Journal websites were performed for the final
2 years of the search period (2016 and 2017)
using the terms ‘‘prevalence’’ and ‘‘interstitial
lung disease’’. In addition, manual reviews of
reference lists of publications that met the
inclusion criteria were performed to maximise
the comprehensiveness of the search.
Eligibility Criteria
Inclusion criteria for the literature search
included: non-interventional studies in
humans; studies conducted in Europe or North
America; studies performed in the general pop-
ulation or an ILD patient population; and
studies assessing the prevalence of ILD, the
prevalence of individual ILDs and/or the pro-
portions of patients with individual ILDs.
Results of the search were restricted to full-text
publications in English or German, published
between January 1, 1990 and August 7, 2017.
Abstracts, case reports, case series, editorials,
letters and opinion pieces were excluded. Stud-
ies reporting only on IPF or SSc-ILD were not
included within our literature search, as these
conditions have been the subject of previous
systematic literature searches [15, 16].
Study Selection
Following the removal of duplicate publica-
tions, study selection was accomplished
through a dual-level screening process. First,
abstracts were reviewed to determine whether
the study was observational in nature, per-
formed in one of the target locations, included
an eligible patient population and reported an
outcome of interest. Full-text assessment of the
qualifying publications was then performed by
two reviewers according to the eligibility criteria
outlined above.
Data Extraction and Quality Assessment
Data extraction was performed and checked for
consistency by two reviewers. Extracted data
included: location; data source; study design;
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study period; study population; study setting;
study objectives; case definition; exclusion cri-
teria; baseline demographics; number of cases;
prevalence; and proportion of fibrosing ILDs
and progression (if reported). Where possible (if
not already reported in the publication),
prevalence estimates were recalculated using
the total population as the denominator.
Some publications did not report the preva-
lence of individual ILDs, but instead reported
the overall prevalence of ILD and the propor-
tion of patients within the ILD population with
individual ILDs. In these cases, estimates of the
prevalence of each individual ILD were
obtained by multiplying the overall prevalence
of ILD by the reported proportion of patients
with each individual ILD.
Prevalence of Fibrosing ILD and
Progressive Fibrosing ILDs
Prevalence estimates for individual ILDs with a
progressive fibrosing phenotype were calculated
(per 100,000 people). Estimates were based on
the prevalence of individual ILDs reported in
the literature and, on the basis of these, the
proportion of patients with the given ILD
expected to develop a progressive fibrosing
phenotype was calculated. Proportions expec-
ted to progress were not, for the most part,
available from published data so an exploratory
approach based on a quantitative physician
survey was taken in which expert clinicians,
including both pulmonologists and rheuma-
tologists who had a high publication record and
had participated in guideline development and/
or ILD clinical trials, provided estimates of the
proportion of patients with individual ILDs that
may develop a progressive fibrosing phenotype
[17].
The individual estimated prevalence values
for different ILDs with a progressive fibrosing
phenotype were then summed to estimate the
overall prevalence of progressive fibrosing ILDs
in each publication, so that a prevalence range
for progressive fibrosing ILDs in Europe and
North America could be estimated. Only data
from studies that reported the overall preva-
lence of ILD, as well as the prevalence or
proportion of individual ILDs, were used for
prevalence estimates of progressive fibrosing
ILDs. Studies reporting only on individual ILDs
and their rates of progression were not used for
prevalence estimates of progressive fibrosing
ILDs because of differences in study design,
setting, methodology and patient population
between studies.
A conceptual diagram of prevalence estima-
tion for progressive fibrosing ILDs is presented
in Fig. 1 [5].
Compliance with Ethics Guidelines
This article is based on previously conducted
studies and does not contain any new studies
with human participants or animals performed
by any of the authors.
RESULTS
Systematic Literature Review
A flow diagram of the publications identified for
inclusion is presented in Fig. S1 in the elec-
tronic supplementary material. In total, 1633
publications were identified through literature
searches conducted in MEDLINE and Embase.
After the removal of 340 duplicates, 1251 pub-
lications were excluded on the basis of their
abstracts, as they either did not report on the
outcomes of interest or were not conducted in
North America or Europe. Of the remaining 42
publications, 33 did not meet the eligibility
criteria. Web-based searches and manual review
of reference lists yielded an additional seven
references, providing a total of 16 publications
from which data were extracted [1–3, 18–30].
Six of the studies were conducted in the USA
and 10 were conducted in Europe; 10 were
cohort studies and six had a cross-sectional
design; studies were conducted between 1988
and 2013 and published between 1990 and
2013. Of the 16 identified publications, five
reported data on overall ILD prevalence and 11
reported data on the prevalence of individual
ILDs or the proportion of individual ILDs in the
prevalent ILD population (Table S3).
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ILD Prevalence
Overall ILD prevalence, as reported in five
identified publications from the literature
review, ranged from 6.3 to 76.0 per 100,000
people in four studies in Europe [1, 24, 26, 30]
and was 74.3 per 100,000 people in one study in
the USA [21] (Fig. 2 [1, 21, 24, 26, 30]). Two of
these studies also reported the prevalence of
progressive fibrosing ILD specifically [21, 24].
The first study, conducted in France, estimated
fibrotic idiopathic interstitial pneumonia (in-
cluding IPF, iNSIP and cases with the Interna-
tional Classification of Diseases [ICD] 10th
Revision code for pulmonary fibrosis) preva-
lence at 12.6 per 100,000 people [24]. The sec-
ond study, conducted in New Mexico, USA,
estimated the prevalence of ILD with pul-
monary fibrosis (based on the presence of ICD
code 515) as 29.0 per 100,000 for men and 27.0
per 100,000 for women [21].
The prevalence of other individual ILDs was
reported (or calculated on the basis of the
proportion of patients with individual ILDs
within the ILD population) in 11 identified
publications from the literature review and
varied up to 21.5 per 100,000 people. Some
studies reported zero prevalence for particular
ILDs. The estimated prevalence or prevalence
range for each ILD, including data from studies
that reported prevalence estimates for individ-
ual ILDs, is presented in Fig. 3 [2, 16, 19–26, 30].
Five additional publications were identified
that did not report prevalence data, but did
assess the proportion of patients diagnosed with
individual ILDs within the prevalent ILD pop-
ulation [3, 18, 27–29], with IPF (27.0–32.5%)
and sarcoidosis (33.7–44.7%) being the most
commonly reported (Table S1).
Estimates of Progression
Excluding IPF (which is by definition progres-
sive), 13–40% of patients with ILD were esti-
mated to develop a progressive fibrosing
phenotype, depending on the underlying
Fig. 1 Conceptual diagram of prevalence estimation for
progressive fibrosing ILDs [5]. Figure is not to scale.
‘‘Autoimmune ILDs’’ includes RA-ILD, SSc-ILD, PM-
ILD, DM-ILD, Sjögren’s-ILD, SLE-ILD, CTD-ILD and
MCTD-ILD; ‘‘Non-IPF IIPs’’ includes iNSIP and unclas-
sifiable IIP; ‘‘Environmental ILDs’’ includes asbestosis,
silicosis and coal worker’s pneumonitis. CTD-ILD con-
nective tissue disease-associated interstitial lung disease,
DM-ILD dermatomyositis-associated interstitial lung dis-
ease, HP hypersensitivity pneumonitis, IIP idiopathic
interstitial pneumonia, ILD interstitial lung disease, iNSIP
idiopathic non-specific interstitial pneumonia, IPF idio-
pathic pulmonary fibrosis, MCTD-ILD mixed connective
tissue disease-associated interstitial lung disease, PM-ILD
polymyositis-associated interstitial lung disease, RA-ILD
rheumatoid arthritis-associated interstitial lung disease,
SLE-ILD systemic lupus erythematosus-associated intersti-
tial lung disease, SSc-ILD systemic sclerosis-associated
interstitial lung disease. Adapted with permission of the 
ERS 2020. European Respiratory Journal 51 (5) 1800692;
https://doi.org/10.1183/13993003.00692-2018 Published
17 May 2018
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disease (Table 1) [17, 31–34]. Four studies
describing the proportion of patients with RA-
ILD [31], SSc-ILD [32], polymyositis/dermato-
myositis-associated ILD [33] and sarcoidosis [34]
who had a progressive fibrosing phenotype were
identified in the literature (Table 1). Two of
these studies used pre-specified criteria (diffus-
ing capacity of the lung for carbon monoxide
[DLCO] falling below 40% predicted [31]; rela-
tive decline in FVC of at least 10% or in DLCO of
at least 15% [33]) to define a progressive
fibrosing phenotype. While progression was not
defined in the other two studies, patients whose
disease progressed were identified retrospec-
tively on the basis of worsening lung function
[32] or worsening respiratory symptoms [34].
Prevalence of Progressive Fibrosing ILDs
Of the five studies that reported overall ILD
prevalence, two also reported the prevalence of
various individual ILDs, such as RA-ILD [26, 30],
and two reported the proportion of patients
with individual ILDs within the ILD population
[21, 24], thus enabling prevalence estimates to
be calculated. For these four studies, for which
the prevalence of individual ILDs could be
determined [21, 24, 26, 30], calculated preva-
lence estimates for individual ILDs with a pro-
gressive fibrosing phenotype varied up to 16.7
per 100,000 people (Table 2) [21, 24, 26, 30].
The collective estimated prevalence of progres-
sive fibrosing ILDs ranged from 2.2 to 20 per
100,000 people in Europe [24, 26, 30] and was
28 per 100,000 people in the USA [21].
DISCUSSION
There have been few epidemiological studies
investigating individual ILDs or ILDs overall. In
view of the potential availability of treatment
for progressive fibrosing ILDs, based on clinical
trials that have investigated whether therapies
that slow progression in IPF can serve a similar
function in progressive fibrosing ILDs, quan-
tification of the prevalence of this group of
diseases has become increasingly important. We
present the first systematic review to estimate
Fig. 2 Prevalence of ILD in Europe and the USA. aAs calculated from [21]. bAs reported by [30]. cAs reported by [26]. dAs
reported by [1]. eAs recalculated from [24], using the total population as the denominator. ILD interstitial lung disease
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the overall prevalence of ILD and progressive
fibrosing ILDs in Europe and the USA. We found
that both prevalence estimates were generally
low. Even without applying the criteria for a
progressive fibrosing phenotype, the estimated
prevalence for each specific ILD was low.
Besides IPF (16.7 per 100,000 people), connec-
tive tissue disease-associated interstitial lung
disease (0.5–10.2 per 100,000 people) and sar-
coidosis (1.9–66.1 per 100,000 people) were
most commonly reported. On the basis of
estimates from the literature review and the
results from the physician interviews and survey
[35], 13–40% of patients with individual ILDs
(100% for IPF) were estimated to develop a
progressive fibrosing phenotype, resulting in
prevalence estimates for the progressive fibros-
ing phenotype in individual ILDs of up to 16.7
per 100,000 people for the four studies anal-
ysed. The overall prevalence of progressive
fibrosing ILDs was subsequently estimated at
2.2–28.0 per 100,000 people (2.2 in Belgium, 6.0
Fig. 3 Prevalence of fibrosing ILDs in Europe and the
USA. aAs reported by or calculated from [2, 24, 26]. bAs
reported by or calculated from [24, 26, 30]. cAs reported by
or calculated from [2, 21, 24, 26, 30]. dAs reported by or
calculated from [24, 26]. eAs reported by or calculated from
[2, 21, 24, 26, 30]. fAs reported by [21, 26]. gAs reported by
[16, 21, 26]. hAs reported by or calculated from [24, 30].
iAs reported by or calculated from [2, 19–26, 30]. CTD-
ILD connective tissue disease-associated interstitial lung
disease, DM-ILD dermatomyositis-associated interstitial
lung disease, HP hypersensitivity pneumonitis, IIP idio-
pathic interstitial pneumonia, ILD interstitial lung disease,
iNSIP idiopathic non-specific interstitial pneumonia, IPF
idiopathic pulmonary fibrosis, MCTD-ILD mixed connec-
tive tissue disease-associated interstitial lung disease, PM-
ILD polymyositis-associated interstitial lung disease, RA-
ILD rheumatoid arthritis-associated interstitial lung dis-
ease, SLE-ILD systemic lupus erythematosus-associated
interstitial lung disease, SSc-ILD systemic sclerosis-associ-
ated interstitial lung disease
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Table 1 Proportion of patients with fibrosing ILDs expected to develop a progressive phenotype
ILD Proportion of patients expected to
develop a progressive fibrosing
phenotype (%)
Reference/source Proxy used to determine progression









RA-ILD 40 [31] First occurrence of DLCO\ 40% predicted
(or patients who were too ill to undergo this
testing)































CTD-ILD connective tissue disease-associated interstitial lung disease, DLCO diffusing capacity of the lung for carbon
monoxide, DM-ILD dermatomyositis-associated interstitial lung disease, FVC forced vital capacity, HP hypersensitivity
pneumonitis, HRCT high-resolution computed tomography, ILD interstitial lung disease, iNSIP idiopathic non-specific
interstitial pneumonia, IPF idiopathic pulmonary fibrosis,MCTD-ILD mixed connective tissue disease-associated interstitial
lung disease, N/A not applicable, PM-ILD polymyositis-associated interstitial lung disease, RA-ILD rheumatoid arthritis-
associated interstitial lung disease, SLE-ILD systemic lupus erythematosus-associated interstitial lung disease, SSc-ILD
systemic sclerosis-associated interstitial lung disease
a Sjögren’s ILD, SLE-ILD and CTD/MCTD-ILD were considered to fall under ‘‘Other CTD-ILDs’’, for which a pro-
portion of 24% was reported [35].
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Table 2 Estimated prevalence of progressive fibrosing ILDs per 100,000 people









[21] IPF 22.5 16.7 100 16.7
RA-ILD 5.4 4.0 40 1.6
SSc-ILD 3.5 2.6 32 0.8
PM/DM-
ILD
0.8 0.6 16 0.1
SLE-ILD 2.3 1.7 24 0.4
MCTD-
ILD
0.8 0.6 24 0.1
Sarcoidosis 11.6 8.6 13 1.1
Other 53.1 39.5 18 7.1
Total – 74.3 – 28.0
[24]c IPF 11.5 8.8 100 8.8











Sarcoidosis 45.8 34.8 13 4.5
Other 25.2 19.1 18 3.4
Total – 76.0 – 20
[26] IPF 19.5 3.4 100 3.4
iNSIP 2.8 0.5 32 0.2
HP 2.6 0.5 21 0.1
RA-ILD 4.4 0.8 40 0.3
SSc-ILD 4.6 0.8 32 0.3
PM/DM-
ILD
0.7 0.1 16 0.02
Sjögren’s-
ILD
0.5 0.1 24 0.02
SLE-ILD 0.7 0.1 24 0.02
MCTD-
ILD
0.2 0.04 24 0.01
Sarcoidosis 34.1 5.9 13 0.8
Other 29.9 5.1 18 0.9
Total – 17.3 – 6.0
[30] IPF 20.0 1.3 100 1.3
HP 13.0 0.8 21 0.2
CTD-ILD 7.0 0.5 24 0.1
Sarcoidosis 31.0 1.9 13 0.2
Other 29.0 1.8 18 0.3
Total – 6.3 – 2.2
CTD-ILD, connective tissue disease-associated interstitial lung disease, DM-ILD dermatomyositis-associated interstitial lung disease, HP hypersensitivity
pneumonitis, ILD interstitial lung disease, iNSIP idiopathic non-specific interstitial pneumonia, IPF idiopathic pulmonary fibrosis, MCTD-ILD mixed
connective tissue disease-associated interstitial lung disease, PM-ILD polymyositis-associated interstitial lung disease, RA-ILD rheumatoid arthritis-associated
interstitial lung disease, SLE-ILD systemic lupus erythematosus-associated interstitial lung disease, SSc-ILD systemic sclerosis-associated interstitial lung disease
a Directly reported for [26, 30]; estimated on the basis of overall ILD prevalence and the proportion of patients with each fibrosing ILD for [21, 24]
b Determined as per Table 1
c Estimates recalculated using the total population as the denominator
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in Greece, 20.0 in France and 28.0 in the USA).
Progressive fibrosing ILDs can, therefore, be
considered rare, affecting fewer than 200,000
people in the USA (a prevalence of approxi-
mately 80 per 100,000 people, based on the
2016 adult population) and having an esti-
mated prevalence below the 50 per 100,000
people threshold for orphan status in Europe
[37]. It should also be noted that variations
between countries may reflect the methodolo-
gies used to calculate the estimates rather than
true differences in prevalence [37].
When interpreting these results, the follow-
ing factors should be considered. Studies were
conducted across several distinct geographical
locations in Europe and the USA, with popula-
tion differences potentially resulting in varying
prevalence estimates. In addition, studies were
conducted in different settings, leading to
potential over- or underestimation of preva-
lence. Some studies were based on insurance
claims and codes used for these, without clinical
verification [20, 22], while others were based on
cross-referencing several sources of data to val-
idate each individual diagnosis [3, 18, 23, 25].
In the analysis of patient registry data for resi-
dents of Bernalillo County, New Mexico, USA,
prevalence estimates were likely to be high
owing to the presence of mining as a major
industry and, consequently, higher occupa-
tional exposure to coal and silica relative to the
general population [21]. Conversely, prevalence
estimates from Flanders, Belgium were poten-
tially low because of the exclusion of occupa-
tional ILDs [30]. Studies were based on data
from differing sources, including patient reg-
istries, claims databases, medical records and
surveys. For instance, only cases observed at
respiratory centres where physicians volun-
teered to participate were included in the anal-
ysis of Greek survey data [26]. When medical
records data from residents of the Seine-Saint-
Denis department in France were analysed,
approximately one-quarter of cases identified
from hospital and community records could
not be reviewed because charts were not avail-
able [24]. Studies were also conducted during
different time frames, ranging from 1988 to
2013; classification of ILDs has changed mark-
edly over this time [38–40], which may have
further contributed to the variation in estimates
between studies and could impact the results.
Differences in the terminology and diagnostic
criteria used to define cases between studies
further complicate the ability to directly com-
pare estimates within a given condition;
patients were identified using clinical criteria or
diagnostic guidelines in some studies, whereas
others used ICD coding to identify cases, which
may result in differences in estimation. Pro-
gressive fibrosing ILD is a relatively new disease
construct that is not consistently defined in
either the clinical practice or research context.
Nevertheless, these are the first estimates of
prevalence of progressive fibrosing ILD based on
published literature and inputs from practising
physicians, which meet a current unmet need
in this disease therapy area.
Potential limitations of this systematic liter-
ature review methodology should also be con-
sidered. The literature review was restricted to
prevalence data from studies conducted in
Europe or North America and published in
English or German, identified using our search
strategy. Although all journals indexed in
MEDLINE and Embase were searched, only
American Journal of Respiratory and Critical Care
Medicine, New England Journal of Medicine and
European Respiratory Journal were manually
reviewed in case of indexing delays, limited to
the years 2016 and 2017. Furthermore, studies
reporting only on IPF and SSc-ILD were not
included within our search because these dis-
eases have been analysed in literature reviews
previously [14, 15], meaning that more recent
publications (not within the time frames of the
existing reviews) were not considered. Regard-
ing our approach to determine the prevalence
of progressive fibrosing ILDs, estimates were
based on four studies that reported overall ILD
prevalence and the prevalence of individual
ILDs or specific ILD proportions [20, 23, 25, 29].
All four studies did not report data for progres-
sive fibrosing ILDs specifically, and estimates of
progression were applied on all studies retro-
spectively based on findings from the physician
survey. The use of expert opinion to predict
prevalence of progression in this way has not
been validated and is open to question. Studies
reporting only prevalence estimates for
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individual ILDs, and not for ILD overall
[28, 31–33], were not included in the calcula-
tion of the overall prevalence of progressive
fibrosing ILDs, as it was not considered
methodologically sound because of significant
differences in study design, setting, methodol-
ogy and patient population. Consideration of
the estimates from these studies may have
resulted in differences in the estimated overall
prevalence of progressive fibrosing ILDs, espe-
cially given the small number of studies upon
which the prevalence calculations were based.
In addition, proxies were used to determine a
progressive fibrosing phenotype for data from
the literature; thus, definitions of progression
vary compared with the physician survey, as
well as between publications [28–31]. Another
limitation is related to the progressive pheno-
type of the disease being defined by lung func-
tion decline and/or worsening symptoms or
imaging, independent of prior treatment
received. In the INBUILD trial of nintedanib in
this setting [7], patients were selected on the
basis of a progressive phenotype despite con-
ventional therapy. As prior therapy could not be
assessed from the literature review of these 16
studies, it is unclear what proportion of the
cases here were identified as having a progres-
sive phenotype that may in fact be responsive to
immunomodulation therapy, possibly overesti-
mating the prevalence of the progressive
phenotype.
Although the prevalence estimates calcu-
lated in this review should be considered pre-
liminary (i.e. as the first estimate based on a
literature review), this represents an important
step in understanding the epidemiology of
progressive fibrosing ILDs.
CONCLUSION
This systematic review provides an overview of
the available literature on the prevalence of ILD,
and the prevalence and proportion of patients
with individual ILDs, in addition to the first
estimate of prevalence of progressive fibrosing
ILDs combining published literature and
physician surveys. Progressive fibrosing ILDs
have an estimated prevalence of between 2.2
and 20.0 per 100,000 people in Europe and 28.0
per 100,000 people in the USA, and can there-
fore be considered rare, based on current crite-
ria. The data in this literature review lay the
groundwork for other future epidemiological
studies to be conducted on the prevalence of
progressive fibrosing ILDs, and hopefully will
give rise to a broadened awareness of these rare
diseases and the unmet needs associated with
them.
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